Connective tissue growth factor and cardiac diastolic dysfunction: Human data from the Taiwan Diastolic Heart Failure Registry and molecular basis by cellular and animal models

European Journal of Heart Failure

Volumn 16, Issue 2, 2014, Pages 163-172

  Wu, Cho Kai ^a,b   Wang, Yi Chih ^a,b   Lee, Jen Kuang ^c,d   Chang, Sheng Nan ^a,b   Su, Mao Yuan ^c   Yeh, Huei Ming ^c   Su, Ming Jai ^a   Chen, Jin Jer ^e   Chiang, Fu Tien ^a,c   Hwang, Juey Jen ^a   Lin, Jiunn Lee ^a   Tsai, Chia Ti ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Canine model; Connective tissue growth factor; Diastolic heart failure; Fibrosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CONNECTIVE TISSUE GROWTH FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXPERIMENTAL DOG; EXTRACELLULAR SPACE; FEMALE; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; TISSUE DOPPLER IMAGING;

CANINE MODEL; CONNECTIVE TISSUE GROWTH FACTOR; DIASTOLIC HEART FAILURE; FIBROSIS;

AGED; ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; DOGS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FIBROSIS; HEART FAILURE, DIASTOLIC; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MICE; MIDDLE AGED; MYOCARDIUM; MYOCYTES, CARDIAC; REGISTRIES; SEVERITY OF ILLNESS INDEX;

EID: 84896959006     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.33     Document Type: Article

References (48)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfeld MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
2. Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003;41:1519-1522.
3. Yturralde RF, Gaasch WH. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis 2005;47:314-319.
4. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948-1955.
5. Lin CY, Wu CK, Yeong EK, Lin HH, Huang YT, Lee JK, Lin YH, Chiang FT, Tang YB, Tsai CT. Prognostic significance of left ventricular diastolic function in burn patients. Shock 2012;37:457-462.
6. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-2467.
7. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001;103:2055-2059.
8. Sciarretta S, Paneni F, Palano F, Chin D, Tocci G, Rubattu S, Volpe M. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009;116:467-477.
9. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-389.
10. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995;92:4862-4866.
11. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997;95:1247-1252.
12. 2+ ATPase. Crit Care Med 2011;39:984-992.
13. Lee JK, Lin HH, Tsai CT, Chen JJ, Kuo CC, Lien YC, Lin JW, Huang JW, Hwang SW, Hwang JJ, Tseng CD, Chiang FT, Wu CK. Differential association of proinflammatory cytokines with left ventricular diastolic dysfunction in subjects with and without continuous ambulatory peritoneal dialysis. Nutr Metab Cardiovasc Dis 2012;22:974-980.
14. Dai QM, Lu J, Liu NF. Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor. Chin Med J (Engl) 2011;124:89-94.
15. Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y, Yokota T, Hamaguchi S, Sunagawa K. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res 2007;30:439-449.
16. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008;19:133-144.
17. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000;32:1805-1819.
18. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, Van Der Made I, Herias V, Van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009;104:170-178.
19. Wu CK, Tsai CT, Chang YC, Luo JL, Wang YC, Hwang JJ, Lin JL, Tseng CD, Chiang FT. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. J Hypertens 2009;27:502-507.
20. Wu CK, Luo JL, Tsai CT, Huang YT, Cheng CL, Lee JK, Lin LY, Lin JW, Hwang JJ, Chiang FT. Demonstrating the pharmacogenetic effects of angiotensinconverting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J 2010;10:46-53.
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
22. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-193.
23. Ciampi Q, Pratali L, Citro R, Villari B, Picano E, Sicari R. Additive value of severe diastolic dysfunction and contractile reserve in the identification of responders to cardiac resynchronization therapy. Eur J Heart Fail 2011;13:1323-1330.
24. Lee JJ, Liu S, Nacif MS, Ugander M, Han J, Kawel N, Sibley CT, Kellman P, Arai AE, Bluemke DA. Myocardial t1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson 2010;13:75.
25. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced t1 mapping. J Am Coll Cardiol 2008;52:1574-1580.
26. Nagatomo Y, Carabello BA, Coker ML, McDermott PJ, Nemoto S, Hamawaki M, Spinale FG. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 2000;278:H151-H161.
27. Tsai CT, Lin JL, Lai LP, Lin CS, Huang SK. Membrane translocation of small GTPase Rac1 and activation of STAT1 and STAT3 in pacing-induced sustained atrial fibrillation. Heart Rhythm 2008;5:1285-1293.
28. Ott C, Iwanciw D, Graness A, Giehl K, Goppelt-Struebe M. Modulation of the expression of connective tissue growth factor by alterations of the cytoskeleton. J Biol Chem 2003;278:44305-44311.
29. Cheng WP, Wang BW, Chen SC, Chang H, Shyu KG. Mechanical stretch induces the apoptosis regulator PUMA in vascular smooth muscle cells. Cardiovasc Res 2012;93:181-189.
30. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010;122:138-144.
31. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiology of heart failure. Eur Heart J 1997;18:208-225.
32. Benjamin IJ. Targeting endoglin, an auxiliary TGF-beta coreceptor, to prevent fibrosis and heart failure. Circulation 2012;125:2689-2691.
33. Miyazaki Y, Ikeda Y, Shiraishi K, Fujimoto SN, Aoyama H, Yoshimura K, Inui M, Hoshijima M, Kasahara H, Aoki H, Matsuzaki M. Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling. PLoS One 2012;7:e35875.
34. Zhang Y, Edgley AJ, Cox AJ, Powell AK, Wang B, Kompa AR, Stapleton DI, Zammit SC, Williams SJ, Krum H, Gilbert RE, Kelly DJ. Ft011, a new antifibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. Eur J Heart Fail 2012;14:549-562.
35. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 2002;21:473-482.
36. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y, Maeno T, Nishida T, Kubota S, Takigawa M, Kurabayashi M. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007;49:1120-1127.
37. Kemp TJ, Aggeli IK, Sugden PH, Clerk A. Phenylephrine and endothelin-1 upregulate connective tissue growth factor in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2004;37:603-606.
38. El Mesallamy HO, Ahmed HH, Bassyouni AA, Ahmed AS. Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy. Clin Biochem 2012;45:646-650.
39. Tong Z, Chen R, Alt DS, Kemper S, Perbal B, Brigstock DR. Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes. Hepatology 2009;50:939-947.
40. Koitabashi N, Arai M, Niwano K, Watanabe A, Endoh M, Suguta M, Yokoyama T, Tada H, Toyama T, Adachi H, Naito S, Oshima S, Nishida T, Kubota S, Takigawa M, Kurabayashi M. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 2008;10:373-379.
41. Hirota Y. A clinical study of left ventricular relaxation. Circulation 1980;62:756-763.
42. Tschope C, Paulus WJ. Is echocardiographic evaluation of diastolic function useful in determining clinical care? Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures. Circulation 2009;120:810-820.
43. Nishimura RA, Tajik AJ. Evaluation of diastolic flling of left ventricle in health and disease: doppler echocardiography is the clinician's Rosetta stone. J Am Coll Cardiol 1997;30:8-18.
44. Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, Goetze JP, Jensen JS. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation 2009;119:2679-2685.
45. Chuva De Sousa Lopes SM, Feijen A, Korving J, Korchynskyi O, Larsson J, Karlsson S, Ten Dijke P, Lyons KM, Goldschmeding R, Doevendans P, Mummery CL. Connective tissue growth factor expression and smad signaling during mouse heart development and myocardial infarction. Dev Dyn 2004;231:542-550.
46. Ivkovic S, Yoon BS, Popoff SN, Safadi FF, Libuda DE, Stephenson RC, Daluiski A, Lyons KM. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003;130:2779-2791.
47. Ahmed MS, Gravning J, Martinov VN, Von Lueder TG, Edvardsen T, Czibik G, Moe IT, Vinge LE, Oie E, Valen G, Attramadal H. Mechanisms of novel cardioprotective functions of ccn2/ctgf in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2011;300:H1291-H1302.
48. Gravning J, Orn S, Kaasboll OJ, Martinov VN, Manhenke C, Dickstein K, Edvardsen T, Attramadal H, Ahmed MS. Myocardial connective tissue growth factor (ccn2/ctgf) attenuates left ventricular remodeling after myocardial infarction. PLoS One 2012;7:e52120.